WestPark Capital Announces Closing of $1,240,000 Vantix Offering
LOS ANGELES, Dec. 13, 2012 /PRNewswire/ -- WestPark Capital announced today the closing of an offering of $1,240,000 for Vantix Diagnostics, Inc. Vantix Diagnostics is the developer of a point of care blood analyzer that produces reference laboratory quality results quickly in a doctor's office without the need for any specialist operator training. The Vantix System (VT-1) is a comprehensive point of care (POC) diagnostics platform based on a sophisticated biosensor technology. Using this patented technology, the Vantix system generates results comparable to those generated by reference laboratories. The system is used in a physician's office, requires no specialist training and the results are produced in less than 10 minutes. The company believes the system presents an opportunity to move reference lab testing to the POC.
For further information please contact WestPark Capital
About WestPark Capital
WestPark Capital, Inc., (www.wpcapital.com) is a full-service investment bank focused on emerging growth sectors such as healthcare, software, technology, biotechnology, financial services, manufacturing, consumer products, media and telecom industries, among other categories. WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements, SIPOs and corporate finance advisory services. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them. Member: FINRA/SIPC.
WestPark Capital, Inc.
Richard Rappaport, CEO
SOURCE WestPark Capital, Inc.